News
Laurent Pharmaceuticals Presents Results from Phase 2 Clinical Study of LAU-7b in Cystic Fibrosis at the NACFC 2022
3 November 2022
LAU-7b first inflammation-controlling drug to demonstrate clinical benefit in adults with CF, complementary to administration of CFTR modulators.Study achieves clinically meaningful...
Read MoreLaurent Pharmaceuticals to present at the North American Cystic Fibrosis Conference
4 October 2022
Laurent Pharmaceuticals to present at the North American Cystic Fibrosis Conference, November 3-5, 2022, Philadelphia, PA
Read MoreEVENTS
Laurent Pharma to participate to BIO International Convention, June 13-16, 2022 – San Diego, CA
Laurent Pharma to participate to BIO-Europe Spring, March 28-31, 2022
Laurent Pharma to participate to BiotechGate, February 7-9, 2022
Laurent Pharma to participate to Biotech Showcase, January 9-11 and 17-19, 2022
Laurent Pharma to participate to H.C. Wainwright 23rd Annual Global Investment Conference,
September 13-15, 2021
September 13-15, 2021